O'NEIL PATRICK R. 4
4 · IONIS PHARMACEUTICALS INC · Filed Oct 8, 2025
Insider Transaction Report
Form 4
O'NEIL PATRICK R.
EVP CLO & General Counsel
Transactions
- Sale
Common Stock
2025-10-06$69.89/sh−10,200$712,849→ 57,130 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-10-06−10,200→ 17,000 totalExercise: $52.87From: 2025-01-02Exp: 2034-01-01→ Common Stock (10,200 underlying) - Exercise/Conversion
Common Stock
2025-10-06$52.87/sh+10,200$539,274→ 67,330 total - Sale
Common Stock
2025-10-06$69.27/sh−3,241$224,488→ 53,889 total
Footnotes (3)
- [F1]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 2, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.70 to $70.075 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.1912 to $69.32 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.